.jpg)
Medidata Secures Top Honors in Everest Group's Decentralized Clinical Trial Platforms PEAK Matrix
Medidata, a
Dassault Systèmes company and leading provider of clinical trial solutions to
the life sciences industry, has again been recognized as a Leader in Everest
Group’s recently published “Decentralized Clinical Trials Platforms PEAK Matrix® Assessment
2023.” Medidata was the only provider to receive a “Star Performer”
designation for the second consecutive year, reflecting its continued
innovation and leadership.
The report
evaluated the vision, capabilities, and market impact of 22 decentralized
clinical trial (DCT) platform providers based on relevant customer case
studies, revenue, key offerings, and their latest progress.
“Medidata’s unified
platform harnesses DCT technology to optimize patient, site, and sponsor
experiences, delivering more inclusive studies,” said Anthony Costello, chief
executive officer, Medidata Patient Cloud, Medidata. “We’re honored to be
recognized as a Leader by Everest Group in DCT platform providers,
demonstrating our extensive experience and leadership in a rapidly evolving
industry.”
In this year’s
assessment, Medidata distinguished itself through substantial investments in
next-generation and patient-centric DCT technologies within Medidata AI and
Medidata Patient Cloud, such as the Medidata Diversity Program, the myMedidata application, and Medidata Rave Companion. As a Leader, Medidata was also
recognized for its domain expertise and user experience for patients and sites,
as well as its global capabilities to orchestrate DCTs.
“Medidata offers an
end-to-end, comprehensive DCT platform, covering ePRO/eCOA, eConsent,
televisits, patient recruitment, and engagement. With deep domain expertise,
strategic partnerships, and industry experience, Medidata has achieved
widespread adoption of its solutions,” said Nisarg Shah, practice director at
Everest Group. “Its investments in building a unified experience for sites and
patients have positioned Medidata as a Leader and a Star Performer in the
Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023.”
Medidata’s platform
has powered nearly 1,700 DCTs and over 1.1 million patients across disease
areas, countries, languages, and clinical trial phases. With this technology,
Medidata supports patient participation in the right trial at the right time,
from anywhere and with easier, faster, and better results.
Leave A Comment